{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:08:44Z","timestamp":1792069724136,"version":"4.4.0"},"reference-count":110,"publisher":"American Society of Hematology","issue":"14","license":[{"start":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T00:00:00Z","timestamp":1652745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,10,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Since its initial identification in 1992 as a possible class 1 cell-surface receptor without a known parent ligand, receptor tyrosine kinase\u2013like orphan receptor 1 (ROR1) has stimulated research, which has made apparent its significance in embryonic development and cancer. Chronic lymphocytic leukemia (CLL) was the first malignancy found to have distinctive expression of ROR1, which can help distinguish leukemia cells from most noncancer cells. Aside from its potential utility as a diagnostic marker or target for therapy, ROR1 also factors in the pathophysiology of CLL. This review is a report of the studies that have elucidated the expression, biology, and evolving strategies for targeting ROR1 that hold promise for improving the therapy of patients with CLL or other ROR1-expressing malignancies.<\/jats:p>","DOI":"10.1182\/blood.2021014760","type":"journal-article","created":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T18:20:59Z","timestamp":1652811659000},"page":"1583-1591","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":96,"title":["ROR1: an orphan becomes apparent"],"prefix":"10.1182","volume":"140","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0064-4549","authenticated-orcid":false,"given":"Thomas J.","family":"Kipps","sequence":"first","affiliation":[{"name":"Center for Novel Therapeutics, Moores Cancer Center, Department of Medicine, University of California, San Diego, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"36","key":"2022100615441581700_bib1","doi-asserted-by":"crossref","first-page":"26181","DOI":"10.1016\/S0021-9258(18)35733-8","article-title":"A\u00a0novel family of cell surface receptors with tyrosine kinase-like domain","volume":"267","author":"Masiakowski","year":"1992","journal-title":"J\u00a0Biol Chem"},{"issue":"1","key":"2022100615441581700_bib2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1046\/j.1365-2443.1999.00234.x","article-title":"Spatio-temporally regulated expression of receptor tyrosine kinases, mRor1, mRor2, during mouse development: implications in development and function of the nervous system","volume":"4","author":"Oishi","year":"1999","journal-title":"Genes Cells"},{"issue":"15","key":"2022100615441581700_bib3","doi-asserted-by":"crossref","first-page":"7109","DOI":"10.1073\/pnas.90.15.7109","article-title":"Dror, a potential neurotrophic receptor gene, encodes a Drosophila homolog of the vertebrate Ror family of Trk-related receptor tyrosine kinases","volume":"90","author":"Wilson","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1-2","key":"2022100615441581700_bib4","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0925-4773(01)00383-5","article-title":"Expression of the receptor tyrosine kinase genes, Ror1 and Ror2, during mouse development","volume":"105","author":"Matsuda","year":"2001","journal-title":"Mech Dev"},{"issue":"6","key":"2022100615441581700_bib5","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s00429-004-0381-6","article-title":"Expression and regulation of ROR-1 during early avian limb development","volume":"207","author":"Rodriguez-Niedenf\u00fchr","year":"2004","journal-title":"Anat Embryol (Berl)"},{"issue":"8","key":"2022100615441581700_bib6","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1002\/dvdy.22362","article-title":"Mice lacking the orphan receptor ror1 have distinct skeletal abnormalities and are growth retarded","volume":"239","author":"Lyashenko","year":"2010","journal-title":"Dev Dyn"},{"issue":"21","key":"2022100615441581700_bib7","doi-asserted-by":"crossref","first-page":"5993","DOI":"10.1073\/pnas.1522512113","article-title":"ROR1 is essential for proper innervation of auditory hair cells and hearing in humans and mice","volume":"113","author":"Diaz-Horta","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"issue":"24","key":"2022100615441581700_bib8","doi-asserted-by":"crossref","first-page":"8329","DOI":"10.1128\/MCB.21.24.8329-8335.2001","article-title":"Loss of mRor1 enhances the heart and skeletal abnormalities in mRor2-deficient mice: redundant and pleiotropic functions of mRor1 and mRor2 receptor tyrosine kinases","volume":"21","author":"Nomi","year":"2001","journal-title":"Mol Cell Biol"},{"issue":"11","key":"2022100615441581700_bib9","doi-asserted-by":"crossref","first-page":"4044","DOI":"10.1073\/pnas.1200421109","article-title":"Wnt5a-Ror-Dishevelled signaling constitutes a core developmental pathway that controls tissue morphogenesis","volume":"109","author":"Ho","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"2022100615441581700_bib10","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1073\/pnas.0712148105","article-title":"Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a","volume":"105","author":"Fukuda","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"2022100615441581700_bib11","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/j.leukres.2011.06.021","article-title":"ROR1 is expressed on hematogones (non-neoplastic human B-lymphocyte precursors) and a minority of precursor-B acute lymphoblastic leukemia","volume":"35","author":"Broome","year":"2011","journal-title":"Leuk Res"},{"issue":"22","key":"2022100615441581700_bib12","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2010-05-283309","article-title":"The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor","volume":"116","author":"Hudecek","year":"2010","journal-title":"Blood"},{"issue":"12","key":"2022100615441581700_bib13","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1158\/1078-0432.CCR-16-2083","article-title":"Analysis of ROR1 protein expression in human cancer and normal tissues","volume":"23","author":"Balakrishnan","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"suppl","key":"2022100615441581700_bib14","doi-asserted-by":"crossref","first-page":"S167","DOI":"10.1016\/j.clml.2015.02.010","article-title":"Pre-clinical specificity and safety of UC-961, a first-in-class monoclonal antibody targeting ROR1","volume":"15","author":"Choi","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"2022100615441581700_bib15","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0092-8674(91)90633-A","article-title":"A\u00a0new nomenclature for int-1 and related genes: the Wnt gene family","volume":"64","author":"Nusse","year":"1991","journal-title":"Cell"},{"issue":"12","key":"2022100615441581700_bib16","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1161\/CIRCRESAHA.110.219840","article-title":"An updated overview on Wnt signaling pathways: a prelude for more","volume":"106","author":"Rao","year":"2010","journal-title":"Circ Res"},{"key":"2022100615441581700_bib17","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.sbi.2014.10.003","article-title":"Extracellular modulators of Wnt signalling","volume":"29","author":"Malinauskas","year":"2014","journal-title":"Curr Opin Struct Biol"},{"issue":"11","key":"2022100615441581700_bib18","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1084\/jem.194.11.1639","article-title":"Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia","volume":"194","author":"Rosenwald","year":"2001","journal-title":"J\u00a0Exp Med"},{"issue":"11","key":"2022100615441581700_bib19","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.2976.2976","article-title":"Immune therapy for chronic lymphocytic leukemia induces the antibody response against a novel tumor-associated antigen, the orphan tyrosine kinase receptor ROR1","volume":"106","author":"Fukuda","year":"2005","journal-title":"Blood"},{"issue":"13","key":"2022100615441581700_bib20","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1182\/blood-2009-09-242438","article-title":"Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway","volume":"115","author":"Lapalombella","year":"2010","journal-title":"Blood"},{"issue":"11","key":"2022100615441581700_bib21","doi-asserted-by":"crossref","first-page":"e0142310","DOI":"10.1371\/journal.pone.0142310","article-title":"Spontaneous immunity against the receptor tyrosine Kinase ROR1 in patients with chronic lymphocytic leukemia","volume":"10","author":"Hojjat-Farsangi","year":"2015","journal-title":"PLoS One"},{"issue":"5","key":"2022100615441581700_bib22","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/ijc.23587","article-title":"Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy","volume":"123","author":"Daneshmanesh","year":"2008","journal-title":"Int J Cancer"},{"issue":"2","key":"2022100615441581700_bib23","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1158\/1078-0432.CCR-07-1823","article-title":"Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia","volume":"14","author":"Baskar","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2022100615441581700_bib24","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/08820130500496878","article-title":"A\u00a0quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry","volume":"35","author":"Olejniczak","year":"2006","journal-title":"Immunol Invest"},{"issue":"6","key":"2022100615441581700_bib25","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.stem.2018.05.018","article-title":"Phase I trial: cirmtuzumab inhibits ROR1 signaling and stemness signatures in patients with chronic lymphocytic leukemia","volume":"22","author":"Choi","year":"2018","journal-title":"Cell Stem Cell"},{"issue":"25","key":"2022100615441581700_bib26","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1182\/blood-2016-04-712562","article-title":"High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia","volume":"128","author":"Cui","year":"2016","journal-title":"Blood"},{"issue":"10","key":"2022100615441581700_bib27","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.leukres.2011.04.006","article-title":"Use of the receptor tyrosine kinase-like orphan receptor 1 (ROR1) as a diagnostic tool in chronic lymphocytic leukemia (CLL)","volume":"35","author":"Uhrmacher","year":"2011","journal-title":"Leuk Res"},{"issue":"1","key":"2022100615441581700_bib28","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/cyto.b.21595","article-title":"Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: an European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project","volume":"94","author":"Rawstron","year":"2018","journal-title":"Cytometry B Clin Cytom"},{"issue":"11","key":"2022100615441581700_bib29","article-title":"Which markers should the used for diagnostic chronic lymphocytic leukemia immunophenotyping scoring system by flow cytometry?","volume":"65","author":"Falay","year":"2019","journal-title":"Clin Lab"},{"key":"2022100615441581700_bib30","doi-asserted-by":"crossref","first-page":"597730","DOI":"10.3389\/fonc.2020.597730","article-title":"Highly sensitive and accurate assessment of minimal residual disease in chronic lymphocytic leukemia using the novel CD160-ROR1 assay","volume":"10","author":"Farren","year":"2020","journal-title":"Front Oncol"},{"issue":"6","key":"2022100615441581700_bib31","doi-asserted-by":"crossref","first-page":"e346","DOI":"10.1111\/bjh.16910","article-title":"ROR1 is an accurate and reliable marker of minimal residual disease in chronic lymphocytic leukaemia","volume":"190","author":"De Propris","year":"2020","journal-title":"Br J Haematol"},{"issue":"2","key":"2022100615441581700_bib32","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s40487-021-00172-2","article-title":"Differential levels of mRNAs in normal B lymphocytes, monoclonal B lymphocytosis and chronic lymphocytic leukemia cells from the same family identify susceptibility genes","volume":"9","author":"Alshahrani","year":"2021","journal-title":"Oncol Ther"},{"issue":"4","key":"2022100615441581700_bib33","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1182\/blood-2015-02-585059","article-title":"Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification","volume":"126","author":"Strati","year":"2015","journal-title":"Blood"},{"issue":"6","key":"2022100615441581700_bib34","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/j.ajpath.2012.08.024","article-title":"The onco-embryonic antigen ROR1 is expressed by a variety of human cancers","volume":"181","author":"Zhang","year":"2012","journal-title":"Am J Pathol"},{"issue":"3","key":"2022100615441581700_bib35","doi-asserted-by":"crossref","first-page":"e31127","DOI":"10.1371\/journal.pone.0031127","article-title":"ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth","volume":"7","author":"Zhang","year":"2012","journal-title":"PLoS One"},{"issue":"48","key":"2022100615441581700_bib36","doi-asserted-by":"crossref","first-page":"17266","DOI":"10.1073\/pnas.1419599111","article-title":"Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy","volume":"111","author":"Zhang","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"2022100615441581700_bib37","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/j.celrep.2018.01.053","article-title":"Commonly occurring cell subsets in high-grade serous ovarian tumors identified by single-cell mass cytometry","volume":"22","author":"Gonzalez","year":"2018","journal-title":"Cell Rep"},{"issue":"1","key":"2022100615441581700_bib38","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/hon.948","article-title":"ROR1 expression is not a unique marker of CLL","volume":"29","author":"Barna","year":"2011","journal-title":"Hematol Oncol"},{"issue":"4","key":"2022100615441581700_bib39","doi-asserted-by":"crossref","first-page":"843","DOI":"10.3109\/10428194.2012.731599","article-title":"Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies","volume":"54","author":"Daneshmanesh","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2022100615441581700_bib40","first-page":"119","article-title":"Comparative expression profile of orphan receptor tyrosine kinase ROR1 in Iranian patients with lymphoid and myeloid leukemias","volume":"3","author":"Shabani","year":"2011","journal-title":"Avicenna J Med Biotechnol"},{"issue":"24","key":"2022100615441581700_bib41","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1182\/blood.2020008404","article-title":"ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient-derived xenograft mouse models","volume":"137","author":"Vaisitti","year":"2021","journal-title":"Blood"},{"issue":"6","key":"2022100615441581700_bib42","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1038\/leu.2011.362","article-title":"Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells","volume":"26","author":"Daneshmanesh","year":"2012","journal-title":"Leukemia"},{"issue":"2","key":"2022100615441581700_bib43","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1073\/pnas.1308374111","article-title":"ROR1 can interact with TCL1 and enhance leukemogenesis in E\u03bc-TCL1 transgenic mice","volume":"111","author":"Widhopf","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"2022100615441581700_bib44","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","article-title":"Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia","volume":"94","author":"Hamblin","year":"1999","journal-title":"Blood"},{"issue":"6","key":"2022100615441581700_bib45","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","article-title":"Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia","volume":"94","author":"Damle","year":"1999","journal-title":"Blood"},{"issue":"10","key":"2022100615441581700_bib46","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1182\/blood.2020010029","article-title":"Exploring the pathways to chronic lymphocytic leukemia","volume":"138","author":"Stevenson","year":"2021","journal-title":"Blood"},{"issue":"2","key":"2022100615441581700_bib47","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1158\/1078-0432.CCR-15-0154","article-title":"Autocrine signaling by Wnt-5a deregulates chemotaxis of leukemic cells and predicts clinical outcome in chronic lymphocytic leukemia","volume":"22","author":"Janovska","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2022100615441581700_bib48","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1172\/JCI83535","article-title":"Wnt5a induces ROR1\/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation","volume":"126","author":"Yu","year":"2016","journal-title":"J\u00a0Clin Invest"},{"issue":"13","key":"2022100615441581700_bib49","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1182\/blood.2019001366","article-title":"Cirmtuzumab blocks Wnt5a\/ROR1 stimulation of NF-\u03baB to repress autocrine STAT3 activation in chronic lymphocytic leukemia","volume":"134","author":"Chen","year":"2019","journal-title":"Blood"},{"issue":"3","key":"2022100615441581700_bib50","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1182\/blood.V99.3.1030","article-title":"Distinctive features of \u201cnurselike\u201d cells that differentiate in the context of chronic lymphocytic leukemia","volume":"99","author":"Tsukada","year":"2002","journal-title":"Blood"},{"issue":"4","key":"2022100615441581700_bib51","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/PPO.0000000000000536","article-title":"Mining the microenvironment for therapeutic targets in chronic lymphocytic leukemia","volume":"27","author":"Kipps","year":"2021","journal-title":"Cancer J"},{"issue":"7","key":"2022100615441581700_bib52","doi-asserted-by":"crossref","first-page":"e11859","DOI":"10.1371\/journal.pone.0011859","article-title":"Stat3 activates the receptor tyrosine kinase like orphan receptor-1 gene in chronic lymphocytic leukemia cells","volume":"5","author":"Li","year":"2010","journal-title":"PLoS One"},{"issue":"11","key":"2022100615441581700_bib53","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.4049\/jimmunol.1900389","article-title":"STAT3-induced Wnt5a provides chronic lymphocytic leukemia cells with survival advantage","volume":"203","author":"Rozovski","year":"2019","journal-title":"J\u00a0Immunol"},{"issue":"40","key":"2022100615441581700_bib54","doi-asserted-by":"crossref","first-page":"10731","DOI":"10.1073\/pnas.1708264114","article-title":"MicroRNA dysregulation to identify therapeutic target combinations for chronic lymphocytic leukemia","volume":"114","author":"Rassenti","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"issue":"24","key":"2022100615441581700_bib55","doi-asserted-by":"crossref","first-page":"15524","DOI":"10.1073\/pnas.242606799","article-title":"Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia","volume":"99","author":"Calin","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"issue":"17","key":"2022100615441581700_bib56","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa050995","article-title":"A\u00a0MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia","volume":"353","author":"Calin","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"39","key":"2022100615441581700_bib57","doi-asserted-by":"crossref","first-page":"13944","DOI":"10.1073\/pnas.0506654102","article-title":"miR-15 and miR-16 induce apoptosis by targeting BCL2","volume":"102","author":"Cimmino","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"2022100615441581700_bib58","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s13238-014-0059-7","article-title":"ROR1, an embryonic protein with an emerging role in cancer biology","volume":"5","author":"Borcherding","year":"2014","journal-title":"Protein Cell"},{"issue":"3","key":"2022100615441581700_bib59","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1748-1716.2011.02306.x","article-title":"Post-translational modifications regulate signalling by Ror1","volume":"203","author":"Kauck\u00e1","year":"2011","journal-title":"Acta Physiol (Oxf)"},{"issue":"10","key":"2022100615441581700_bib60","doi-asserted-by":"crossref","first-page":"e78339","DOI":"10.1371\/journal.pone.0078339","article-title":"The tyrosine kinase receptor ROR1 is constitutively phosphorylated in chronic lymphocytic leukemia (CLL) cells","volume":"8","author":"Hojjat-Farsangi","year":"2013","journal-title":"PLoS One"},{"key":"2022100615441581700_bib61","doi-asserted-by":"crossref","first-page":"838871","DOI":"10.3389\/fcell.2022.838871","article-title":"Lyn phosphorylates and controls ROR1 surface dynamics during chemotaxis of CLL cells","volume":"10","author":"Dave","year":"2022","journal-title":"Front Cell Dev Biol"},{"issue":"10","key":"2022100615441581700_bib62","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1002\/ijc.28879","article-title":"The ROR1 pseudokinase diversifies signaling outputs in MET-addicted cancer cells","volume":"135","author":"Gentile","year":"2014","journal-title":"Int J Cancer"},{"issue":"1","key":"2022100615441581700_bib63","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.bbamcr.2012.10.010","article-title":"Protein tyrosine kinase regulation by ubiquitination: critical roles of Cbl-family ubiquitin ligases","volume":"1833","author":"Mohapatra","year":"2013","journal-title":"Biochim Biophys Acta"},{"issue":"6877","key":"2022100615441581700_bib64","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/416187a","article-title":"The endophilin-CIN85-Cbl complex mediates ligand-dependent downregulation of c-Met","volume":"416","author":"Petrelli","year":"2002","journal-title":"Nature"},{"issue":"35","key":"2022100615441581700_bib65","doi-asserted-by":"crossref","first-page":"36259","DOI":"10.1074\/jbc.M402469200","article-title":"Cbl-mediated degradation of Lyn and Fyn induced by constitutive fibroblast growth factor receptor-2 activation supports osteoblast differentiation","volume":"279","author":"Kaabeche","year":"2004","journal-title":"J\u00a0Biol Chem"},{"key":"2022100615441581700_bib66","doi-asserted-by":"crossref","first-page":"104512","DOI":"10.1016\/j.phrs.2019.104512","article-title":"Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in\u00a0vivo","volume":"151","author":"Liu","year":"2020","journal-title":"Pharmacol Res"},{"issue":"4","key":"2022100615441581700_bib67","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1365-2141.2010.08362.x","article-title":"Silencing of ROR1 and FMOD with siRNA results in apoptosis of CLL cells","volume":"151","author":"Choudhury","year":"2010","journal-title":"Br J Haematol"},{"issue":"4","key":"2022100615441581700_bib68","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.neuroscience.2009.11.056","article-title":"Ror1-Ror2 complexes modulate synapse formation in hippocampal neurons","volume":"165","author":"Paganoni","year":"2010","journal-title":"Neuroscience"},{"issue":"9","key":"2022100615441581700_bib69","doi-asserted-by":"crossref","first-page":"a011189","DOI":"10.1101\/cshperspect.a011189","article-title":"PI3K-PKB\/Akt pathway","volume":"4","author":"Hemmings","year":"2012","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"7","key":"2022100615441581700_bib70","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1038\/s41418-020-0496-1","article-title":"NF-\u03baB-p62-NRF2 survival signaling is associated with high ROR1 expression in chronic lymphocytic leukemia","volume":"27","author":"Sanchez-Lopez","year":"2020","journal-title":"Cell Death Differ"},{"issue":"5","key":"2022100615441581700_bib71","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.molcel.2013.08.003","article-title":"Phosphorylation of p62 activates the Keap1-Nrf2 pathway during selective autophagy","volume":"51","author":"Ichimura","year":"2013","journal-title":"Mol Cell"},{"issue":"17","key":"2022100615441581700_bib72","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1089\/ars.2017.7342","article-title":"Transcriptional Regulation by Nrf2","volume":"29","author":"Tonelli","year":"2018","journal-title":"Antioxid Redox Signal"},{"issue":"1","key":"2022100615441581700_bib73","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1146\/annurev-pharmtox-011112-140320","article-title":"Role of nrf2 in oxidative stress and toxicity","volume":"53","author":"Ma","year":"2013","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"6","key":"2022100615441581700_bib74","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1038\/s41375-020-01055-7","article-title":"Wnt5a enhances proliferation of chronic lymphocytic leukemia and ERK1\/2 phosphorylation via a ROR1\/DOCK2-dependent mechanism","volume":"35","author":"Hasan","year":"2021","journal-title":"Leukemia"},{"issue":"12","key":"2022100615441581700_bib75","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1038\/leu.2017.132","article-title":"Wnt5a induces ROR1 to associate with 14-3-3\u03b6 for enhanced chemotaxis and proliferation of chronic lymphocytic leukemia cells","volume":"31","author":"Yu","year":"2017","journal-title":"Leukemia"},{"issue":"2","key":"2022100615441581700_bib76","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1182\/blood-2017-12-819383","article-title":"Wnt5a induces ROR1 to recruit DOCK2 to activate Rac1\/2 in chronic lymphocytic leukemia","volume":"132","author":"Hasan","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"2022100615441581700_bib77","article-title":"Wnt5a induces ROR1 to interact Grb2 to enhance Ras activation in chronic lymphocytic leukemia","volume":"138","author":"Hasan","year":"2021","journal-title":"Blood"},{"issue":"12","key":"2022100615441581700_bib78","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1038\/leu.2017.133","article-title":"Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells","volume":"31","author":"Hasan","year":"2017","journal-title":"Leukemia"},{"issue":"3","key":"2022100615441581700_bib79","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/s41375-018-0306-7","article-title":"Wnt5a causes ROR1 to complex and activate cortactin to enhance migration of chronic lymphocytic leukemia cells","volume":"33","author":"Hasan","year":"2019","journal-title":"Leukemia"},{"issue":"1","key":"2022100615441581700_bib80","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41523-019-0131-9","article-title":"Wnt5a induces ROR1 to recruit cortactin to promote breast-cancer migration and metastasis","volume":"5","author":"Hasan","year":"2019","journal-title":"NPJ Breast Cancer"},{"issue":"9","key":"2022100615441581700_bib81","doi-asserted-by":"crossref","first-page":"11947","DOI":"10.1007\/s13277-016-5039-5","article-title":"Dishevelled proteins are significantly upregulated in chronic lymphocytic leukaemia","volume":"37","author":"Khan","year":"2016","journal-title":"Tumour Biol"},{"issue":"1","key":"2022100615441581700_bib82","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1600-065X.1993.tb00843.x","article-title":"Association of Src-family kinase Lyn with B-cell antigen receptor","volume":"132","author":"Yamamoto","year":"1993","journal-title":"Immunol Rev"},{"issue":"5","key":"2022100615441581700_bib83","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.ccr.2012.08.027","article-title":"Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia","volume":"22","author":"Bicocca","year":"2012","journal-title":"Cancer Cell"},{"issue":"6","key":"2022100615441581700_bib84","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/leu.2016.368","article-title":"Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib","volume":"31","author":"Yu","year":"2017","journal-title":"Leukemia"},{"issue":"24","key":"2022100615441581700_bib85","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1182\/bloodadvances.2017010215","article-title":"Crosstalk between ROR1 and BCR pathways defines novel treatment strategies in mantle cell lymphoma","volume":"1","author":"Karvonen","year":"2017","journal-title":"Blood Adv"},{"issue":"37","key":"2022100615441581700_bib86","doi-asserted-by":"crossref","first-page":"24731","DOI":"10.18632\/oncotarget.25340","article-title":"Cirmtuzumab inhibits ibrutinib-resistant, Wnt5a-induced Rac1 activation and proliferation in mantle cell lymphoma","volume":"9","author":"Yu","year":"2018","journal-title":"Oncotarget"},{"issue":"16 suppl","key":"2022100615441581700_bib87","article-title":"Wnt5a induces DOCK1 to complex with ROR1 and activate Rac1 leading to enhanced growth of breast cancer cells","volume":"80","author":"Hasan","year":"2020","journal-title":"Cancer Res"},{"issue":"6","key":"2022100615441581700_bib88","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/PPO.0000000000000416","article-title":"Targeted therapy in chronic lymphocytic leukemia","volume":"25","author":"Kipps","year":"2019","journal-title":"Cancer J"},{"issue":"6","key":"2022100615441581700_bib89","doi-asserted-by":"crossref","first-page":"e21018","DOI":"10.1371\/journal.pone.0021018","article-title":"Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies","volume":"6","author":"Yang","year":"2011","journal-title":"PLoS One"},{"issue":"3","key":"2022100615441581700_bib90","doi-asserted-by":"crossref","first-page":"349","DOI":"10.4161\/mabs.19870","article-title":"Targeting malignant B cells with an immunotoxin against ROR1","volume":"4","author":"Baskar","year":"2012","journal-title":"MAbs"},{"issue":"2","key":"2022100615441581700_bib91","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.cell.2018.03.034","article-title":"Machine learning identifies stemness features associated with oncogenic dedifferentiation","volume":"173","author":"Malta","year":"2018","journal-title":"Cell"},{"issue":"25","key":"2022100615441581700_bib92","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"8","key":"2022100615441581700_bib93","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.4049\/jimmunol.1801327","article-title":"Cutting edge: ROR1\/CD19 receptor complex promotes growth of mantle cell lymphoma cells independently of the B cell receptor-BTK signaling pathway","volume":"203","author":"Zhang","year":"2019","journal-title":"J\u00a0Immunol"},{"issue":"15 suppl","key":"2022100615441581700_bib94","article-title":"Phase 1\/2 study of cirmtuzumab and ibrutinib in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL)","volume":"39","author":"Lee","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"2022100615441581700_bib95","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-022-01543-y","article-title":"High expression level of ROR1 and ROR1-signaling associates with venetoclax resistance in chronic lymphocytic leukemia","author":"Ghia","year":"2022","journal-title":"Leukemia"},{"issue":"5","key":"2022100615441581700_bib96","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1182\/blood.2018882290","article-title":"ROR1-targeted delivery of miR-29b induces cell cycle arrest and therapeutic benefit in\u00a0vivo in a CLL mouse model","volume":"134","author":"Chiang","year":"2019","journal-title":"Blood"},{"issue":"2","key":"2022100615441581700_bib97","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/leu.2014.199","article-title":"Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia","volume":"29","author":"Mani","year":"2015","journal-title":"Leukemia"},{"issue":"16","key":"2022100615441581700_bib98","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1182\/bloodadvances.2020003276","article-title":"The ROR1 antibody-drug conjugate huXBR1-402-G5-PNU effectively targets ROR1+ leukemia","volume":"5","author":"Hu","year":"2021","journal-title":"Blood Adv"},{"issue":"21","key":"2022100615441581700_bib99","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.1637.1637","article-title":"Cirmtuzumab vedotin (UC-961ADC3), an anti-ROR1-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for ROR1-positive leukemia and solid tumors","volume":"122","author":"Cui","year":"2013","journal-title":"Blood"},{"issue":"suppl 1","key":"2022100615441581700_bib100","article-title":"Development of cirmtuzumab antibody-drug conjugates (ADCs) targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1)","volume":"132","author":"Mian","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2022100615441581700_bib101","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s13045-021-01143-w","article-title":"The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma","volume":"14","author":"Jiang","year":"2021","journal-title":"J\u00a0Hematol Oncol"},{"issue":"1","key":"2022100615441581700_bib102","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100001","article-title":"Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers","volume":"1","author":"Wang","year":"2021","journal-title":"NEJM Evid"},{"issue":"24","key":"2022100615441581700_bib103","doi-asserted-by":"crossref","first-page":"E5467","DOI":"10.1073\/pnas.1719905115","article-title":"Potent and selective antitumor activity of a T cell-engaging bispecific antibody targeting a membrane-proximal epitope of ROR1","volume":"115","author":"Qi","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"issue":"16","key":"2022100615441581700_bib104","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1182\/blood-2018-12-852376","article-title":"Taking a \u201cBiTE out of ALL\u201d: blinatumomab approval for MRD-positive ALL","volume":"133","author":"Curran","year":"2019","journal-title":"Blood"},{"issue":"15 suppl","key":"2022100615441581700_bib105","article-title":"NVG-111, a novel ROR1xCD3 bispecific antibody for non-Hodgkin lymphoma [abstract]","volume":"39","author":"Granger","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"2022100615441581700_bib106","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1038\/s41375-018-0113-1","article-title":"First-in-class oral small molecule inhibitor of the tyrosine kinase ROR1 (KAN0439834) induced significant apoptosis of chronic lymphocytic leukemia cells","volume":"32","author":"Hojjat-Farsangi","year":"2018","journal-title":"Leukemia"},{"issue":"8","key":"2022100615441581700_bib107","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1158\/0008-5472.CAN-10-2662","article-title":"Ror1 is a pseudokinase that is crucial for Met-driven tumorigenesis","volume":"71","author":"Gentile","year":"2011","journal-title":"Cancer Res"},{"issue":"12","key":"2022100615441581700_bib108","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1158\/1078-0432.CCR-13-0330","article-title":"Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells","volume":"19","author":"Hudecek","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2022100615441581700_bib109","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1158\/2326-6066.CIR-14-0127","article-title":"The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in\u00a0vivo antitumor activity","volume":"3","author":"Hudecek","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"2022100615441581700_bib110","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1158\/2326-6066.CIR-14-0163","article-title":"Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells","volume":"3","author":"Berger","year":"2015","journal-title":"Cancer Immunol Res"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/140\/14\/1583\/1923584\/blood_bld-2021-014760-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/140\/14\/1583\/1923584\/blood_bld-2021-014760-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T15:45:48Z","timestamp":1665071148000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/140\/14\/1583\/485278\/ROR1-an-orphan-becomes-apparent"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,6]]},"references-count":110,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2022,10,6]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2021014760","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,6]]}}}